{
    "clinical_study": {
        "@rank": "30094", 
        "acronym": "YES-P", 
        "arm_group": [
            {
                "arm_group_label": "Standard of care treatment", 
                "arm_group_type": "Active Comparator", 
                "description": "All patients in the Control group will receive SOC treatment with sorafenib in accordance with the package insert."
            }, 
            {
                "arm_group_label": "TheraSphere", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive treatment with yttrium-90 microspheres in accordance with the package insert."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a two-arm, open-label, prospective, multi-center, randomized, active-controlled\n      clinical trial to assess efficacy and safety of TheraSphere in comparison to standard of\n      care therapy (sorafenib) in the treatment of patients with inoperable liver cancer and\n      blockage of the portal vein."
        }, 
        "brief_title": "Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Unresectable Hepatocellular Carcinoma With Portal Vein Thrombosis", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Thrombosis", 
                "Venous Thrombosis", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "The objective of this phase III, prospective randomized trial is to determine whether\n      TheraSphere provides a meaningful benefit in survival in comparison with the standard of\n      care (sorafenib) in patients with good hepatic function and advanced hepatocellular\n      carcinoma (HCC) associated with portal vein thrombosis (PVT).\n\n      This is an open-label prospective, multi-center, randomized, controlled clinical trial that\n      will evaluate the use of TheraSphere compared to standard-of-care sorafenib alone."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients over 18 years of age, regardless of race of gender\n\n          -  Advanced unresectable hepatocellular carcinoma with branch portal vein thrombosis\n             (confirmed by non-invasive criteria EASL/AASLD, mandatory by histology in\n             non-cirrhotic patients); can be naive or recurrent HCC after curative treatment (> 6\n             months before randomization)\n\n          -  Unilobar disease\n\n          -  Child Pugh A\n\n          -  Tumor volume \u2264 70% of liver volume (determined by visual estimation)\n\n          -  At least one uni-dimensional HCC target lesion assessable by CT or MRI according to\n             RECIST 1.1\n\n          -  ECOG Performance Status 0-1\n\n          -  Platelets \u2265 50 X 10\u00b3/\u00b5L\n\n          -  WBC \u2265 1.5 X10\u00b3/\u00b5L\n\n          -  AST/ALT \u2264 5 X upper limit of normal\n\n          -  Creatinine \u2264 2.0 mg/dL\n\n          -  Life expectancy > 3 months\n\n          -  Signed informed consent\n\n        Exclusion Criteria:\n\n          -  Confirmed extra hepatic metastases. Patients with indeterminate hepatic hilar lymph\n             nodes up to 2.5 cm in greatest dimension, or with indeterminate lung nodules (single\n             lesion between 1-1.5 cm, or multiple smaller lesions with a total diameter \u2264 2 cm)\n             may be included if metastatic disease is deemed unlikely\n\n          -  Known contraindication to standard-of-care sorafenib including allergic reaction,\n             pill swallowing difficulty, uncontrolled hypertension or history of cardiac disease,\n             significant GI bleed within 30 days, renal failure including dialysis\n\n          -  Evidence of hepatic vein invasion or caval thrombosis\n\n          -  Evidence of chronic obstructive pulmonary disease\n\n          -  Indication for any possible curative treatment after multidisciplinary assessment\n             (surgery, ablation, transplantation)\n\n          -  Previous treatment with sorafenib for more than 4 weeks during the previous 2 months;\n             prior sorafenib-related toxicity\n\n          -  Initiation of anti-tumor therapy including chemotherapy or investigational drug\n             treatment within 30 days before beginning study\n\n          -  Prior TACE < 6 months prior to screening phase in case of patients progressing from\n             an intermediate to an advanced stage due to occurrence of PVT\n\n          -  Patients cannot be on a transplant list\n\n          -  History of organ allograft\n\n          -  Contraindications to angiography or selective visceral catheterization\n\n          -  History of severe allergy or intolerance to contrast agents, narcotics, sedatives or\n             atropine that cannot be managed  medically\n\n          -  Prior external beam radiation therapy to the liver\n\n          -  Evidence of continuing adverse effect of prior therapy\n\n          -  Active GI bleeding and any bleeding diathesis or coagulopathy that is not correctable\n             by usual therapy or hemostatic agents\n\n          -  Evidence of any disease or condition that would place the patient at undue risk and\n             preclude safe use of TheraSphere treatment\n\n          -  Females of child-bearing potential must have a negative serum test Participation in\n             concurrent clinical trials"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "328", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01887717", 
            "org_study_id": "TS-104", 
            "secondary_id": "2012-005375-14"
        }, 
        "intervention": [
            {
                "arm_group_label": "TheraSphere", 
                "intervention_name": "TheraSphere", 
                "intervention_type": "Device", 
                "other_name": "yttrium-90 microspheres"
            }, 
            {
                "arm_group_label": "Standard of care treatment", 
                "description": "standard of care therapy for treatment of advanced hepatocellular carcinoma", 
                "intervention_name": "Sorafenib", 
                "intervention_type": "Drug", 
                "other_name": "Nexavar"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sorafenib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "hepatocellular carcinoma", 
            "portal vein thrombosis"
        ], 
        "lastchanged_date": "March 28, 2014", 
        "location": [
            {
                "contact": {
                    "email": "carlene.castillo@northwestern.edu", 
                    "last_name": "Carlene del Castillo", 
                    "phone": "312-695-1518"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern Medical Faculty Foundation, Div of Hematology/Oncology"
                }, 
                "investigator": {
                    "last_name": "Laura Kulik, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "federica.brunero@istitutotumori.mi.it", 
                    "last_name": "Federica Brunero", 
                    "phone": "+39 02 2390 3238"
                }, 
                "contact_backup": {
                    "email": "simona.marchesi@istitutotumori.mi.it", 
                    "last_name": "Simona Marchesi", 
                    "phone": "+39 02 2390 3256"
                }, 
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "zip": "I-20133"
                    }, 
                    "name": "Fondazione Istituto Nazionale Tumori di Milano"
                }, 
                "investigator": {
                    "last_name": "Prof Vincenzo Mazzaferro, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "IRENGEL@clinic.ub.es", 
                    "last_name": "Ingrid Rengel", 
                    "phone": "+34 9322 79235"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08036"
                    }, 
                    "name": "Hospital Cl\u00ednic Barcelona. IDIBAPS. CIBEREHD. Liver Unit"
                }, 
                "investigator": {
                    "last_name": "Jordi Bruix, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mgadelhuph@gmail.com", 
                    "last_name": "Maca Gomez", 
                    "phone": "+1 34 607 944 154"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28222"
                    }, 
                    "name": "Hospital Universitario Puerta de Hierro, Gastroenterology & Hepatology Dept"
                }, 
                "investigator": {
                    "last_name": "Jose L Calleja, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "anacatgre@gmail.com", 
                    "last_name": "Ana Catala", 
                    "phone": "+1 34 687565382"
                }, 
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46026"
                    }, 
                    "name": "Hospital Universitari i Politecnic la Fe"
                }, 
                "investigator": {
                    "last_name": "Daniel Perez-Enguix, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Jodie.Hodgson@uhb.nhs.uk", 
                    "last_name": "Jodie Hodgson", 
                    "phone": "+1 44 121 697 8413"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United Kingdom", 
                        "zip": "B15 2WB"
                    }, 
                    "name": "University Hospitals Birmingham NHS Foundation Trust"
                }, 
                "investigator": {
                    "last_name": "Yuk Ting Ma, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sarahamilton@nhs.net", 
                    "last_name": "Sara Hamilton", 
                    "phone": "+44 0207 794 0500", 
                    "phone_ext": "35590"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "NW3 2QG"
                    }, 
                    "name": "Royal Free London NHS Foundation Trust"
                }, 
                "investigator": {
                    "last_name": "Tim Meyer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Italy", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere\u00ae) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)", 
        "overall_official": [
            {
                "affiliation": "Istituto Tumori Nazionale, Milan, Italy", 
                "last_name": "Vincenzo Mazzaferro, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Northwestern University, Chicago, Illinois", 
                "last_name": "Riad Salem, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "Italy: Agenzia Italiana del Farmaco (AIFA) & Ministero della Salute", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "primary endpoint is overall survival measured from time of randomization", 
            "measure": "survival", 
            "safety_issue": "No", 
            "time_frame": "from time of randomization up to 36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01887717"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Adverse events classified according to Common Terminology Criteria for Adverse Events v4.0 (CTCAE) will be assessed on the basis of frequency and severity", 
                "measure": "adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "from randomization up to 36 months"
            }, 
            {
                "description": "Radiological time to progression will be assessed using multiple methodologies", 
                "measure": "time to progression", 
                "safety_issue": "No", 
                "time_frame": "from randomization up to 36 months"
            }
        ], 
        "source": "BTG International Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Biocompatibles UK Ltd", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "BTG International Inc.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}